Drug Profile
Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/Tillotts
Alternative Names: Anti-TNF therapy - Numab/Tillotts; Antibody-based inflammatory bowel disease therapeutics - Numab/Tillotts; ND-009; NM 09 programme; NM-09; TNF-alpha blockers - Numab/Tillotts; TNF-α inhibitor antibodies- Numab/Tillotts; Tumour necrosis factor-alpha blockers - Numab/TillottsLatest Information Update: 09 Sep 2020
Price :
$50
*
At a glance
- Originator Numab
- Developer Numab; Tillotts Pharma
- Class Anti-inflammatories; Antibodies; Immunoglobulin Fv fragments
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 26 Aug 2020 ND 009 is available for licensing as of 26 Aug 2020. https://www.tillotts.com/partnering/partner-with-tillotts/ (Numab pipeline, August 2020)
- 28 Jul 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Switzerland (Parenteral)
- 09 Jun 2015 TNF-α inhibitor antibodies licensed to Tillotts Pharma worldwide for the treatment of inflammatory bowel disease